**The Product Development Partnership (PDP)**

An innovative model to accelerate health technology development

**What is a PDP?**

A product development partnership (PDP) is a **non-profit organization** that develops innovative and affordable medicines and tools for populations affected by **poverty-related and neglected tropical diseases**.

PDPs focus on **unmet patient needs** by designing products for use in **low- and middle-income countries** with high disease burdens.

PDPs can work from **early discovery** to **product delivery implementation**, covering either specific research gaps or the full innovation cycle.

PDPs employ a **portfolio approach** to R&D to accelerate product development, pursuing multiple strategies for a disease area and allowing **only the most promising products** to move forward.

**Why do we need PDPs?**

- **Infectious and neglected diseases cause immense suffering worldwide.**
- **These diseases affect more than half the world’s population, particularly those living in Africa and Asia.**
- **Millions need affordable drugs as they are too poor to pay for the products of the latest scientific research.**

PDPs enable innovative research, development and delivery of new drugs, helping to save millions of lives.

**Malaria**

- Takes the life of a child **every 2 minutes**
- Can kill **within 24 hrs** of symptom onset
- Threatens **almost half the world’s population**
- **Deprives African countries of US$12–30 billion** every year
- Is associated with drug resistance in Southeast Asia, where an estimated > **20 million cases** occur each year
- Is both a cause and consequence of poverty and predominantly affects **vulnerable populations** such as pregnant women and children


**Medicines for Malaria Venture**

In response to the malaria burden and the empty malaria drug pipeline, MMV was launched in 1999. Our mission is to discover, develop and facilitate delivery of new, effective and affordable antimalarial drugs for vulnerable populations in disease-endemic countries.

While the antimalarial drug market is huge in terms of those in need, it is small in terms of profit, making it difficult for pharmaceutical companies to invest alone...

...so MMV shares the costs and risks of drug development with partners and makes antimalarial drug research happen.

Defeating Malaria Together

www.mmv.org
Over 1 million lives saved since 2009 by seven MMV-co-developed medicines.

Medicines for Malaria Venture
An example of a world-leading PDP

MMV’s strengths

A global partnership network: > 400 partners in > 50 countries. MMV pools existing resources and expertise for malaria R&D.

$1 = $3.50

A strong contractual framework: MMV and contracted partners commit to developing products that will be accessible and affordable to populations at risk of malaria.

Clear picture of goals from the outset: MMV defines the required characteristics of new malaria molecules and works to identify them. With partners, we combine these molecules into medicines to meet globally agreed ‘Target Product Profiles’.

A virtuous circle: Direct and in-kind support from our pharma partners more than triples the value of each donor dollar for R&D.

Value for money: Supervising a portfolio of > 65 antimalarial R&D projects, MMV ensures the most efficient allocation of funds to fulfil its mission.

In-depth expertise: MMV staff have 592 accumulated years of scientific expertise and 205 years of malaria experience.

MMV and partners’ key achievements

100 million vials of Artesun® (Guilin Pharmaceutical’s injectable artesunate) delivered to treat children with severe malaria, saving an estimated additional 650,000 lives compared with quinine treatment.

In 2017, tafenoquine became the first potential new medicine for relapsing malaria to be submitted for stringent regulatory approval in more than 60 years.

Pyramax® granules (pyronaridine-artesunate), co-developed with Shin Poong Pharmaceutical: a new medicine for children, added to the WHO list of prequalified medicines.

19 new malaria drug targets validated since 1999.

Over 350 million courses of Novartis’ Coartem Dispersible supplied to 50 malaria-endemic countries since 2009.

1st quality-assured artesunate suppository for pre-referral management of severe malaria: with MMV’s support, Cipla received a 12-month authorization for procurement from the Global Fund.

73 million courses of SP+AQ shipped to countries in the Sahel region of West Africa in 2016 by MMV’s partner Guilin Pharmaceutical: enough to provide 18 million children with seasonal malaria chemoprotection.

Over 1 million lives saved since 2009 by seven MMV-co-developed medicines.

9 potential new medicines in clinical development, prioritising treatment for vulnerable populations and supporting malaria eradication.